Chlorphenesin carbamate + hydroxychloroquine is under clinical development by Oncocross and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Chlorphenesin carbamate + hydroxychloroquine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chlorphenesin carbamate + hydroxychloroquine overview
A combination of chlorphenesin carbamate (OC-201) and hydroxychloroquine (OC-202) is under development for the treatment of metastasic pancreatic cancer . The drug candidate is developed based on ONCO AI platform technology. It is administered through oral route.
It was under development for the treatment of cancer invasion in biliary, colon cancer.
Oncocross overview
Oncocross is a medical technology company that provides a platform based on artificial intelligence that allows patients to receive the best care and precision medicine, as well as pharmaceutical companies. The Company is headquartered in Mapo-gu, Seoul, South Korea.
For a complete picture of Chlorphenesin carbamate + hydroxychloroquine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
